The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The role of selinexor in NHL
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, discusses the role of selinexor in non-Hodgkin lymphoma (NHL), commenting on the efficacy and safety of this drug. Whilst selinexor has shown promising efficacy in the relapsed/refractory (R/R) setting, it is known to cause significant toxicity. In addition, treatment with single-agent selinexor is less effective that doublet and triplet therapies. According to Dr Kuruvilla, it is important to better understand how to use selinexor. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck
